Can a consumer DNA test interpret CYP2C19 reliably?

Consumer DNA tests can reliably detect common CYP2C19 variants (e.g., *2, *3, *17) and assign metabolizer status (poor, intermediate, normal, rapid, ultrarapid) with reasonable accuracy. Most direct-to-consumer genotyping arrays are validated for these SNPs. However, limitations exist: rare or population-specific variants may be missed, and test accuracy varies by platform and laboratory. The interpretation relies on reference databases that may not be fully representative of all ethnic groups. For clinical decisions – such as adjusting clopidogrel, omeprazole, or antidepressant doses – confirmatory testing in a certified pharmacogenetic laboratory is recommended. CPIC guidelines consider CYP2C19 evidence strong, but they apply to validated clinical tests, not necessarily all consumer products. Overall, the interpretation is reliable for common phenotypes but not infallible. Evidence is rated human-moderate because most validation studies were conducted in adults of European ancestry.